[Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer

计划入组 48 人 · 首次发布于 2024 年 1 月 29 日

A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma

计划入组 2 人 · 首次发布于 2016 年 12 月 20 日

Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

计划入组 26 人 · 首次发布于 2018 年 2 月 22 日

Actinium-225 CAM FAP

CAM-FAP

AC-225

AC Immune

Switzerland

Enlaces Academicos Internac Ac

Mexico

AC NEWCO PTY LTD

Australia

Precirix Receives FDA Clearance to Begin Phase 1 Trial of CAM-FAP-Ac-225 Targeted Alpha Therapy

Ratio Therapeutics Doses First Patients in Phase 1/2 Trial of FAP-Targeted Radiopharmaceutical for Aggressive Sarcomas

FDA Clears IND for Full-Life's Actinium-225 c-MET Radioconjugate [225Ac]Ac-FL-261 in Non-Squamous NSCLC